Effect of intracanal medicaments on matrix metalloproteinase-9 and vasoactive intestinal peptide secretion in periapical lesions of re-treated canals: a randomized controlled clinical study
| Autor: | Yasin Bayir, Mine Büker Özdemir, Ertuğrul Karataş, Mevlut Albayrak |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Vasoactive intestinal peptide Neuropeptide Enzyme-Linked Immunosorbent Assay Matrix (biology) Matrix metalloproteinase Bone tissue Calcium Hydroxide 03 medical and health sciences 0302 clinical medicine Interstitial fluid Internal medicine Humans Medicine Secretion General Dentistry Root Canal Irrigants business.industry Chlorhexidine 030206 dentistry Endocrinology medicine.anatomical_structure Matrix Metalloproteinase 9 030220 oncology & carcinogenesis Retreatment Female business Periapical Periodontitis Root Canal Preparation Vasoactive Intestinal Peptide medicine.drug |
| Zdroj: | Clinical Oral Investigations. 23:921-928 |
| ISSN: | 1436-3771 1432-6981 |
| DOI: | 10.1007/s00784-018-2517-8 |
| Popis: | The aim of this study was to evaluate the effect of calcium hydroxide (Ca[OH]2) and chlorhexidine (CHX) gel on matrix metalloproteinase-9 (MMP-9) and vasoactive intestinal peptide (VIP) secretion in periapical lesions. A total of 60 patients were randomly divided into two groups that were to receive different medications. Pre-and post-treatment samples were collected from the interstitial fluid of periapical lesions using sterile paper points. VIP and MMP-9 levels were measured by enzyme-linked immunosorbent assay kits, and the data were statistically analyzed. Gender and smoking habits had no effect on the pre- and post-treatment VIP and MMPs levels. Intragroup analyses revealed that in the Ca(OH)2 group, the post-treatment VIP level was found to be significantly higher than the pre-treatment VIP level. In the CHX group, the post-treatment MMP-9 level was significantly higher than the pre-treatment MMP-9 level. According to the results of the present study, the type of the medication affected the amount of periapical VIP and MMP-9 secretion. VIP is a neuropeptide that promotes new bone formation. Thus, intracanal Ca(OH)2 medication may accelerate the repair process of bone tissue. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink